The EUA was based on data from the randomized, double-blind, placebo-controlled ENSEMBLE trial.
Study authors conducted a systematic review and meta-analysis to assess the efficacy of Janus kinase-inhibitors and Type I interferons as potential antiviral candidates for the treatment of COVID-19.
A text message system can monitor postoperative opioid use and shows that many prescribed opioid tablets are unused.
Researchers compared IL-1 and IL-6 inhibition vs standard management in hospitalized patients with COVID-19, respiratory insufficiency, and hyperinflammation.
The NIAID will evaluate the vaccine candidate, mRNA-1273.351, against the SARS-CoV-2 variant, B.1.351.
For patients with advanced melanoma, response to immune checkpoint inhibitors is similar for those with and without preexisting autoimmune disease.
For patients with moderate-to-severe COVID-19, colchicine reduces the length of supplemental oxygen therapy and hospitalization.
The FDA has approved the Patient Specific Talus Spacer for humanitarian use in the treatment of avascular necrosis of the ankle joint.
The American College of Rheumatology developed clinical guidance for the use of COVID-19 vaccines in patients with rheumatic and musculoskeletal diseases.
The FDA has issued an Emergency Use Authorization for Lilly’s SARS-CoV-2 neutralizing antibodies bamlanivimab plus etesevimab.
Investigators determined whether ABO and Rh blood groups were associated with risk for SARS-CoV-2 infection and severe COVID-19 illness.
The number of ADRs associated with hydroxychloroquine and chloroquine more than doubled in 2020 compared with 2018 and 2019.
The EUA submission is based on data from the randomized, double-blind, placebo-controlled ENSEMBLE trial.
Hip fracture survivors experience notable declines in function and well-being in the first year.
Case study of a 37-year-old woman with a unique presentation of an inflammatory disease.